Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

• Published in: Journal of antimicrobial chemotherapy Vol. 44; no. 6; pp. 835 - 838
• Main Authors: SOMAN, A, HONEYBOURNE, D, ANDREWS, J, JEVONS, G, WISE, R
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.12.1999; Oxford Publishing Limited (England)
• Subjects: Anti-Infective Agents - administration & dosage; Anti-Infective Agents - blood; Anti-Infective Agents - pharmacokinetics; Antibacterial agents; Antibiotic Prophylaxis; Antibiotics. Antiinfectious agents. Antiparasitic agents; Aza Compounds; Biological and medical sciences; Body Fluids - chemistry; Bronchi - chemistry; Bronchoscopy; Epithelium - physiology; Female; Fiber Optic Technology; Fluoroquinolones; Humans; Macrophages, Alveolar - chemistry; Male; Medical sciences; Moxifloxacin; Pharmacology. Drug treatments; Quinolines; Respiratory Mucosa - chemistry; Bronchoscopy; Human; Respiratory disease; Single dose; Oral administration; Bronchus; Moxifloxacin; Respiratory system; Infection; Antibiotic; Fluoroquinolone derivatives; Absorption; Pulmonary alveolus; Distribution; Bacteriosis; Epithelial cell; Serum; Lining; Antibacterial agent; Pharmacokinetics; Quinolone derivatives; Optical fiber; Macrophage
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/44.6.835

The concentrations of moxifloxacin achieved after a single 400 mg dose were measured in serum, epithelial lining fluid (ELF), alveolar macrophages (AM) and bronchial mucosa (BM). Concentrations were determined using a microbiological assay. Nineteen patients undergoing fibre-optic bronchoscopy were studied. Mean serum, ELF, AM and BM concentrations at 2.2, 12 and 24 h were as follows: 2.2 h: 3.2 mg/L, 20.7 mg/L, 56.7 mg/L, 5.4 mg/kg; 12 h: 1.1 mg/L, 5.9 mg/L, 54.1 mg/L, 2.0 mg/kg; 24 h: 0.5 mg/L, 3.6 mg/L, 35.9 mg/L, 1.1 mg/kg, respectively. These concentrations exceed the MIC(90)s for common respiratory pathogens such as Streptococcus pneumoniae (0.25 mg/L), Haemophilus influenzae (0.03 mg/L), Moraxella catarrhalis (0.12 mg/L), Chlamydia pneumoniae (0.12 mg/L) and Mycoplasma pneumoniae (0. 12 mg/L) and indicate that moxifloxacin should be effective in the treatment of community-acquired, lower respiratory tract infections.